SG11202104611YA - T cell compositions with improved phenotypic properties - Google Patents

T cell compositions with improved phenotypic properties

Info

Publication number
SG11202104611YA
SG11202104611YA SG11202104611YA SG11202104611YA SG11202104611YA SG 11202104611Y A SG11202104611Y A SG 11202104611YA SG 11202104611Y A SG11202104611Y A SG 11202104611YA SG 11202104611Y A SG11202104611Y A SG 11202104611YA SG 11202104611Y A SG11202104611Y A SG 11202104611YA
Authority
SG
Singapore
Prior art keywords
cell compositions
phenotypic properties
improved phenotypic
improved
properties
Prior art date
Application number
SG11202104611YA
Inventor
Mathias Oelke
Kristi Jones
Sojung Kim
Lauren Suarez
Ken Carter
Scott Carmer
Dan Bednarik
Vineetha Edavana
Emily Lu
Original Assignee
Neximmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neximmune Inc filed Critical Neximmune Inc
Publication of SG11202104611YA publication Critical patent/SG11202104611YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/464449—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464489—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202104611YA 2018-11-08 2019-11-08 T cell compositions with improved phenotypic properties SG11202104611YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862757467P 2018-11-08 2018-11-08
US201962821031P 2019-03-20 2019-03-20
US201962867499P 2019-06-27 2019-06-27
PCT/US2019/060477 WO2020097466A1 (en) 2018-11-08 2019-11-08 T cell compositions with improved phenotypic properties

Publications (1)

Publication Number Publication Date
SG11202104611YA true SG11202104611YA (en) 2021-06-29

Family

ID=70612526

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104611YA SG11202104611YA (en) 2018-11-08 2019-11-08 T cell compositions with improved phenotypic properties

Country Status (12)

Country Link
US (2) US20200188435A1 (en)
EP (1) EP3876979A4 (en)
JP (1) JP2022512948A (en)
KR (1) KR20210095157A (en)
CN (1) CN113226359B (en)
AU (1) AU2019375997A1 (en)
BR (1) BR112021008963A2 (en)
CA (1) CA3118757A1 (en)
IL (1) IL282914A (en)
MX (1) MX2021005372A (en)
SG (1) SG11202104611YA (en)
WO (1) WO2020097466A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113880953A (en) * 2020-07-01 2022-01-04 华夏英泰（北京）生物技术有限公司 T cell antigen receptor, polymer compound thereof, preparation method and application thereof
BR112023022765A2 (en) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh ANTIGEN-BINDING PROTEINS THAT SPECIFICALLY BIND PRAME
JPWO2022234856A1 (en) * 2021-05-07 2022-11-10
CN113388612A (en) * 2021-06-18 2021-09-14 重庆天科雅生物科技有限公司 Primer designed for TCR with epitope point of IYVLVMLVL and application thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
JP3680219B2 (en) * 1994-06-28 2005-08-10 独立行政法人理化学研究所 Induction culture method of cancer cytotoxic T lymphocytes
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
EP0889964A1 (en) 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6140113A (en) 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
DK1257632T3 (en) 2000-02-24 2008-01-28 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
EP1287357A2 (en) 2000-06-02 2003-03-05 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US20040115216A1 (en) 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
JP2006524991A (en) 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド Method for producing and isolating antigen-specific T cells
KR20080048455A (en) 2005-08-08 2008-06-02 폰다지오네 센트로 산 라파엘 델 몬테 테이보 USE OF COMMON Gamma; CHAIN CYTOKINES FOR THE VISUALIZATION, ISOLATION AND GENETIC MODIFICATION OF MEMORY T LYMPHOCYTES
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
US20110256147A1 (en) 2008-12-01 2011-10-20 The Johns Hopkins University Diagnostic and treatment methods for cancer based on immune inhibitors
US8415150B2 (en) 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
KR102095670B1 (en) 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 Compositions and methods of identifying tumor specific neoantigens
EP2404618A1 (en) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US10758487B2 (en) 2011-12-09 2020-09-01 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2791322A1 (en) 2011-12-12 2014-10-22 Cell Medica Limited Process of expanding t cells
US10463750B2 (en) 2013-02-15 2019-11-05 The Johns Hopkins University Antigen-Specific T cell redirectors
CN105431523B (en) 2013-03-14 2020-08-21 约翰·霍普金斯大学 Nanoscale artificial antigen presenting cells
EP3052085B1 (en) 2013-10-03 2019-07-03 University of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of nkt cells
EP3107996B1 (en) * 2014-02-21 2020-02-19 Colmmune, Inc. Tscm cells and methods for use
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3134512B1 (en) 2014-04-24 2019-01-02 Miltenyi Biotec GmbH Method for automated generation of genetically modified t cells
PL3134095T3 (en) 2014-04-25 2020-10-19 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
JP7413639B2 (en) 2014-06-11 2024-01-16 ポリバイオセプト ゲーエムベーハー Lymphocyte expansion using cytokine compositions for active cellular immunotherapy
KR20170078619A (en) 2014-09-17 2017-07-07 더 존스 홉킨스 유니버시티 Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
MA45488A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, KITS AND APPARATUS
AU2016344745A1 (en) 2015-10-28 2018-05-17 Life Technologies As Selective expansion of different subpopulations of T cells by the alteration of cell surfacing signals and signal ratio
MA44314A (en) * 2015-11-05 2018-09-12 Juno Therapeutics Inc CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS
US20180355316A1 (en) * 2015-12-04 2018-12-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method of amplifying a population of antigen-specific memory cd4+ t cells using artificial presenting cells expressing hla class ii molecules
EP3445399A4 (en) * 2016-03-16 2019-10-30 NexImmune, Inc Production of antigen-specific t-cells
AU2018337960A1 (en) * 2017-09-20 2020-04-30 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
US20210254000A1 (en) * 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition

Also Published As

Publication number Publication date
KR20210095157A (en) 2021-07-30
EP3876979A4 (en) 2022-08-24
CN113226359A (en) 2021-08-06
AU2019375997A1 (en) 2021-06-03
US11007222B2 (en) 2021-05-18
IL282914A (en) 2021-06-30
US20200215115A1 (en) 2020-07-09
CN113226359B (en) 2024-05-24
BR112021008963A2 (en) 2021-09-14
JP2022512948A (en) 2022-02-07
CA3118757A1 (en) 2020-05-14
MX2021005372A (en) 2021-09-14
EP3876979A1 (en) 2021-09-15
WO2020097466A1 (en) 2020-05-14
US20200188435A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
IL282914A (en) T cell compositions with improved phenotypic properties
GB201813178D0 (en) Cell
PL3662014T3 (en) Polymer composition with improved mechanical properties
GB201803079D0 (en) Cell
GB201810492D0 (en) Composition
GB201811100D0 (en) Composition
GB201819540D0 (en) T cell modification
GB201812145D0 (en) Composition
GB201804434D0 (en) Composition
PL3601588T3 (en) Phenotypic characterization of cells
IL255664A0 (en) Hematopoietic stem cells with improved properties
PT3899996T (en) Electrolyte compositions
PL3056528T3 (en) Segmented copolymer composition with improved properties
GB201807693D0 (en) Cell
GB202100709D0 (en) Polymer composition
SG11201911924PA (en) Polymer compositions stabilized with organopolysulfides
GB201816399D0 (en) Cell
GB201810024D0 (en) Composition
GB201809123D0 (en) Composition
GB201805918D0 (en) Cell
GB201721129D0 (en) Fuel compositions
GB201801596D0 (en) Composition
HUE062232T2 (en) Solid electrolyte composition
FI20185919A (en) Biodiesel composition
ZA202102573B (en) Fuel compositions